Rationale New approaches to define factors underlying the immunopathogenesis of pulmonary diseases including sarcoidosis and tuberculosis are needed to develop new treatments and biomarkers. Comparing the blood transcriptional response of tuberculosis to other similar pulmonary diseases will advance knowledge of disease pathways and help distinguish diseases with similar clinical presentations. Objectives To determine the factors underlying the immunopathogenesis of the granulomatous diseases, sarcoidosis and tuberculosis, by comparing the blood transcriptional responses in these and other pulmonary diseases. Methods We compared whole blood genome-wide transcriptional profiles in pulmonary sarcoidosis, pulmonary tuberculosis, to community acquired pneumonia and primary lung cancer and healthy controls, before and after treatment, and in purified leucocyte populations. Measurements and Main Results An Interferon-inducible neutrophil-driven blood transcriptional signature was present in both sarcoidosis and tuberculosis, with a higher abundance and expression in tuberculosis. Heterogeneity of the sarcoidosis signature correlated significantly with disease activity. Transcriptional profiles in pneumonia and lung cancer revealed an over-abundance of inflammatory transcripts. After successful treatment the transcriptional activity in tuberculosis and pneumonia patients was significantly reduced. However the glucocorticoid-responsive sarcoidosis patients showed a significant increase in transcriptional activity. 144-blood transcripts were able to distinguish tuberculosis from other lung diseases and controls. Conclusions Tuberculosis and sarcoidosis revealed similar blood transcriptional profiles, dominated by interferon-inducible transcripts, while pneumonia and lung cancer showed distinct signatures, dominated by inflammatory genes. There were also significant differences between tuberculosis and sarcoidosis in the degree of their transcriptional activity, the heterogeneity of their profiles and their transcriptional response to treatment.
References
[1]
WHO (2010) Global tuberculosis control. World Health Organisation.
[2]
Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, et al. (2004) A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 170: 1324–1330.
[3]
Pascual V, Chaussabel D, Banchereau J (2010) A genomic approach to human autoimmune diseases. Annu Rev Immunol 28: 535–571.
[4]
Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, et al. (2010) An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466: 973–977.
[5]
Cliff JM, Lee JS, Constantinou N, Cho JE, Clark TG, et al. (2012) Distinct Phases of Blood Gene Expression Pattern Through Tuberculosis Treatment Reflect Modulation of the Humoral Immune Response. J Infect Dis.
[6]
Maertzdorf J, Repsilber D, Parida SK, Stanley K, Roberts T, et al. (2011) Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 12: 15–22.
[7]
Ottenhoff TH, Dass RH, Yang N, Zhang MM, Wong HE, et al. (2012) Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PloS one 7: e45839.
[8]
Koth LL, Solberg OD, Peng JC, Bhakta NR, Nguyen CP, et al. (2011) Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med 184: 1153–1163.
[9]
Maertzdorf J, Weiner J, 3rd, Mollenkopf HJ, Bauer T, Prasse A, et al (2012) Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A 109: 7853–7858.
[10]
Bloom CI, Graham CM, Berry MP, Wilkinson KA, Oni T, et al. (2012) Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One 7: e46191.
[11]
Costabel U, Hunninghake GW (1999) ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J 14: 735–737.
[12]
Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, et al. (2009) BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64 Suppl 3iii1–55.
[13]
Pankla R, Buddhisa S, Berry M, Blankenship DM, Bancroft GJ, et al. (2009) Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis. Genome Biol 10: R127.
[14]
Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, et al. (2010) TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465: 937–941.
[15]
Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America 98: 5116–5121.
[16]
Rosenbaum JT, Pasadhika S, Crouser ED, Choi D, Harrington CA, et al. (2009) Hypothesis: sarcoidosis is a STAT1-mediated disease. Clin Immunol 132: 174–183.
[17]
Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, et al. (2001) Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164: 1885–1889.
[18]
Lockstone HE, Sanderson S, Kulakova N, Baban D, Leonard A, et al. (2010) Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis. Am J Respir Crit Care Med 181: 1367–1375.
[19]
Fernandez-Serrano S, Dorca J, Coromines M, Carratala J, Gudiol F, et al. (2003) Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 10: 813–820.
[20]
Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL (2011) C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Med 123: 114–119.
[21]
O’Callaghan DS, O’Donnell D, O’Connell F, O’Byrne KJ (2010) The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol 5: 2024–2036.
[22]
Sweiss NJ, Salloum R, Gandhi S, Alegre ML, Sawaqed R, et al. (2010) Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations. PLoS One 5: e9088.
[23]
Ardura MI, Banchereau R, Mejias A, Di Pucchio T, Glaser C, et al. (2009) Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections. PLoS One 4: e5446.
[24]
Cooper AM (2009) Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27: 393–422.
[25]
Manzanillo PS, Shiloh MU, Portnoy DA, Cox JS (2012) Mycobacterium tuberculosis activates the DNA-dependent cytosolic surveillance pathway within macrophages. Cell host & microbe 11: 469–480.
[26]
Pandey AK, Yang Y, Jiang Z, Fortune SM, Coulombe F, et al. (2009) NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS pathogens 5: e1000500.
[27]
Manca C, Tsenova L, Freeman S, Barczak AK, Tovey M, et al. (2005) Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 25: 694–701.
[28]
Novikov A, Cardone M, Thompson R, Shenderov K, Kirschman KD, et al. (2011) Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1beta production in human macrophages. Journal of immunology 187: 2540–2547.
[29]
Gerke AK, Hunninghake G (2008) The immunology of sarcoidosis. Clin Chest Med 29: 379–390, vii.
[30]
Hoffmann RM, Jung MC, Motz R, Gossl C, Emslander HP, et al. (1998) Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol. 28: 1058–1063.
[31]
Chakravarty SD, Harris ME, Schreiner AM, Crow MK (2012) Sarcoidosis Triggered by Interferon-Beta Treatment of Multiple Sclerosis: A Case Report and Focused Literature Review. Semin Arthritis Rheum.
[32]
Gupta D, Agarwal R, Aggarwal AN, Verma I (2011) Immune Responses to Mycobacterial Antigens in Sarcoidosis: A Systematic Review. Ind J Chest Dis 53: 41–49.
[33]
McColl A, Michlewska S, Dransfield I, Rossi AG (2007) Effects of glucocorticoids on apoptosis and clearance of apoptotic cells. ScientificWorldJournal 7: 1165–1181.
[34]
Shipp LE, Lee JV, Yu CY, Pufall M, Zhang P, et al. (2010) Transcriptional regulation of human dual specificity protein phosphatase 1 (DUSP1) gene by glucocorticoids. PLoS One 5: e13754.
[35]
Veenbergen S, Smeets RL, Bennink MB, Arntz OJ, Joosten LA, et al. (2010) The natural soluble form of IL-18 receptor beta exacerbates collagen-induced arthritis via modulation of T-cell immune responses. Ann Rheum Dis 69: 276–283.
[36]
Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, et al. (2002) Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 16: 61–71.
[37]
Paramothayan S, Lasserson TJ, Walters EH (2006) Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane database of systematic reviews: CD003536.
